-Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex ...
CRISPR Therapeutics (NASDAQ:CRSP) said Monday that Vertex Pharmaceuticals (VRTX) subsidiary ViaCyte has elected to opt-out of their development partnership for gene-edited stem cell therapies for the ...
Vertex Therapeutics VRTX announced that it is entering into a new non-exclusive licensing agreement with CRISPR Therapeutics CRSP for the use of the latter’s gene-editing technology, CRISPR/Cas9. The ...
Live Science on MSNOpinion
One molecule could usher revolutionary medicines for cancer, diabetes and genetic disease — but the US is turning its back on it
The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...
With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
A researcher at the University of Houston finds management of diabetic ketoacidosis may center around reducing ketone levels ...
Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...
After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...
CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best biotech stocks to buy. Following CRISPR Therapeutics AG (NASDAQ:CRSP)’s collaboration with Sirius on FXI siRNA SRSD107, BMO Capital reaffirmed ...
-Vertex to receive non-exclusive rights to CRISPR Therapeutics' CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- -CRISPR Therapeutics to receive $100M upfront ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback